LT2005099A - ANTIKuNAI, NUKREIPTI PRIES MONOCITO CHEMOTAKSIO BALTYMA -1, IR JU PANAUDOJIMAS - Google Patents

ANTIKuNAI, NUKREIPTI PRIES MONOCITO CHEMOTAKSIO BALTYMA -1, IR JU PANAUDOJIMAS

Info

Publication number
LT2005099A
LT2005099A LT2005099A LT2005099A LT2005099A LT 2005099 A LT2005099 A LT 2005099A LT 2005099 A LT2005099 A LT 2005099A LT 2005099 A LT2005099 A LT 2005099A LT 2005099 A LT2005099 A LT 2005099A
Authority
LT
Lithuania
Prior art keywords
mcp
antibodies directed
chemo
protein
atractant
Prior art date
Application number
LT2005099A
Other languages
English (en)
Other versions
LT5416B (lt
Inventor
Jean M. Gudas
Mary Haak-Frendscho
Orit Foord
Meina L. Liang
Kiran Ahluwalia
Sunil Bhakta
Original Assignee
Abgenix, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31888391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2005099(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abgenix, Inc. filed Critical Abgenix, Inc.
Publication of LT2005099A publication Critical patent/LT2005099A/lt
Publication of LT5416B publication Critical patent/LT5416B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Isradimo igyvendinimas susijes su antikunais, nukreiptais pries monocitu chemotaksio baltymo-1 (MCP-1) antigena, ir tokiu antikunu panaudojimu. Ypatingai, remiantis kai kuriais igyvendinimais, numatyti pilnai zmogaus monokloniniai antikunai, nukreipti pries MCP-1 antigena. Pateiktos nukleotidu sekos, koduojancios, ir aminorugsciu sekos, apimancios, imunoglobulino molekules sunkiaja ir lengvaja grandines, ypatingai sekos, atitinkancios artimoms sunkiosios ir lengvosios grandines sekoms, apimancioms strukturine sriti ir/arba komplementaruma apibreziancias sritis (CDR), ypatingai nuo FR1 iki FR4 arba CDR1 iki CDR3. Taip pat pateiktos hibridomos ir kitos lasteliu linijos, ekspresuojancios tokias imunoglobulinu molekules ir monokloninius antikunus.
LT2005099A 2002-08-19 2005-11-08 Antikūnai, nukreipti prieš monocito chemotaksio baltymą -1, ir jų panaudojimas LT5416B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40480202P 2002-08-19 2002-08-19

Publications (2)

Publication Number Publication Date
LT2005099A true LT2005099A (lt) 2006-11-27
LT5416B LT5416B (lt) 2007-04-25

Family

ID=31888391

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2005099A LT5416B (lt) 2002-08-19 2005-11-08 Antikūnai, nukreipti prieš monocito chemotaksio baltymą -1, ir jų panaudojimas

Country Status (17)

Country Link
US (3) US7202343B2 (lt)
EP (1) EP1542724A4 (lt)
JP (1) JP4468172B2 (lt)
AU (1) AU2003265575B2 (lt)
CA (1) CA2496419A1 (lt)
CO (1) CO6220978A2 (lt)
HR (1) HRP20050986A2 (lt)
IL (1) IL171674A0 (lt)
IS (1) IS8115A (lt)
LT (1) LT5416B (lt)
ME (1) MEP18108A (lt)
NZ (1) NZ542784A (lt)
RS (1) RS20050834A (lt)
RU (1) RU2339647C2 (lt)
UA (1) UA87979C2 (lt)
WO (1) WO2004016769A2 (lt)
ZA (1) ZA200508994B (lt)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118710B2 (en) * 2000-10-30 2006-10-10 Sru Biosystems, Inc. Label-free high-throughput optical technique for detecting biomolecular interactions
US7575939B2 (en) 2000-10-30 2009-08-18 Sru Biosystems, Inc. Optical detection of label-free biomolecular interactions using microreplicated plastic sensor elements
NZ566539A (en) 2002-09-06 2010-01-29 Medarex Inc Therapeutic human anti-IL-1R1 monoclonal antibody
US7927822B2 (en) 2002-09-09 2011-04-19 Sru Biosystems, Inc. Methods for screening cells and antibodies
US8017113B2 (en) 2003-03-12 2011-09-13 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating an inflammation
ATE394676T1 (de) 2003-03-12 2008-05-15 Rappaport Family Inst For Res Verbindungen und verfahren zur diagnose von prostatakrebs
EP1684703A4 (en) * 2003-11-05 2008-10-01 Centocor Inc METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH MCP-1
US7674884B2 (en) * 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
US8481035B2 (en) 2004-04-27 2013-07-09 Northwestern University Methods for treating chronic pelvic pain syndrome with antibodies that binds MCP-1 or MIP-1A
WO2005113814A2 (en) * 2004-04-27 2005-12-01 Northwestern University Biomarkers of chronic pelvic pain syndrome
ME01803B (me) * 2004-08-05 2010-12-31 Genentech Inc Humanizovani anti-cmet antagonisti
US8114964B2 (en) 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
PE20110071A1 (es) * 2005-05-19 2011-01-31 Centocor Inc Anticuerpos anti-mcp-1, composiciones y metodos
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
CN101443357A (zh) * 2005-08-12 2009-05-27 先灵公司 Mcp1融合物
US20080118437A1 (en) * 2006-03-01 2008-05-22 Regents Of The University Of Michigan Diagnosis and treatment O prostate cancer
CA2653398A1 (en) * 2006-05-26 2007-12-06 Board Of Regents, The University Of Texas System Reverse phase protein array, protein activation and expression signatures, and associated methods
US20090297502A1 (en) * 2006-06-15 2009-12-03 Li Li Ccr2 antagonists for chronic organ transplantation rejection
US7919077B2 (en) * 2006-07-24 2011-04-05 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising CCL2 and use of same for the treatment of inflammation
WO2008077945A2 (en) * 2006-12-22 2008-07-03 Ablynx N.V. Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
EP1958647A1 (en) * 2007-02-15 2008-08-20 Helmholtz-Zentrum für Infektionsforschung GmbH Pharmaceutical composition with bacteria for tumor treatment
CA2692392A1 (en) * 2007-06-29 2009-01-08 Centocor Ortho Biotech Inc. Anti- mcp-1 antibodies, compositions, methods and uses
US9134307B2 (en) 2007-07-11 2015-09-15 X-Body, Inc. Method for determining ion channel modulating properties of a test reagent
CN101802611A (zh) 2007-07-11 2010-08-11 Sru生物系统公司 鉴别离子通道调节剂的方法
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
US7988967B2 (en) * 2007-08-10 2011-08-02 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
JP5641599B2 (ja) * 2007-08-24 2014-12-17 学校法人慶應義塾 腫瘍細胞による免疫抑制の解除剤とそれを用いた抗腫瘍剤
JP2011509156A (ja) 2008-01-08 2011-03-24 イェール ユニバーシティ 血管移植片の開存性を促進するための組成物および方法
US8257936B2 (en) 2008-04-09 2012-09-04 X-Body Inc. High resolution label free analysis of cellular properties
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
JP5646457B2 (ja) * 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
JP5723769B2 (ja) * 2008-06-03 2015-05-27 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
NZ589434A (en) * 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
MX2010014574A (es) * 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
NO2321351T3 (lt) 2008-08-18 2018-03-31
CA2734800C (en) * 2008-08-20 2021-02-09 Probiodrug Ag Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (mcp-1 n1pe)
US8262879B2 (en) 2008-09-03 2012-09-11 Nabsys, Inc. Devices and methods for determining the length of biopolymers and distances between probes bound thereto
EP2350128B1 (en) * 2008-10-22 2014-10-01 Institute for Research in Biomedicine Methods for producing antibodies from plasma cells
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
RU2393216C1 (ru) * 2009-02-06 2010-06-27 Александр Валентинович Шишкин Способ комбинированного иммунологического исследования клеток с помощью биочипа
WO2010107752A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
BR112012004387A2 (pt) 2009-08-28 2015-09-08 Vlst Corp anticorpos anticinas que se l igam a múltiplas quimiocinas cc.
SG178602A1 (en) * 2009-09-01 2012-04-27 Abbott Lab Dual variable domain immunoglobulins and uses thereof
BR112012008833A2 (pt) * 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CN102947705A (zh) * 2010-02-18 2013-02-27 前体生物药物股份公司 通过确定焦谷氨酸修饰的mcp-1诊断炎性疾病的方法和谷氨酰胺酰基环化酶抑制剂的筛选方法
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
SG188190A1 (en) 2010-08-03 2013-04-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
MX2013011706A (es) * 2011-04-07 2014-04-25 Amgen Inc Proteinas novedosas de enlace a antigeno.
US20130004484A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
RU2501017C1 (ru) * 2012-10-18 2013-12-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский институт акушерства и педиатрии" Министерства здравоохранения и социального развития Российской Федерации Способ прогнозирования невынашивания беременности в ранние сроки
MY171664A (en) 2012-11-01 2019-10-22 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
CN105530945A (zh) * 2013-08-06 2016-04-27 国立大学法人九州大学 有机酸聚合物作为有效组分的、预防或抑制癌细胞生存的药物
WO2015035215A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
AU2015259053B2 (en) 2014-05-16 2020-12-24 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CA3007631A1 (en) 2015-12-11 2017-06-15 Research Institute At Nationwide Children's Hospital Optimized patient specific non-linear tissue engineered vascular grafts
WO2018014111A1 (en) 2016-06-22 2018-01-25 Harless William Warren Cancer treatment and metastasis inhibition using an anti-cancer stem cell agent in combination with a neul sialidase inhibitor or a cytokine inhibitor after primary cancer treatment
WO2018106931A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2018148447A1 (en) * 2017-02-08 2018-08-16 Adimab, Llc Antibody heavy chain variable domains targeting the nkg2d receptor
IL268554B2 (en) 2017-02-08 2025-03-01 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CA3235295C (en) 2017-02-20 2024-11-19 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
JP7672196B2 (ja) 2017-03-14 2025-05-07 アムジエン・インコーポレーテツド 細胞培養において産生される抗体の総非フコシル化グリコフォームの調節
CN108048408B (zh) * 2018-01-26 2020-02-07 扬州大学 牛单核细胞趋化蛋白-1杂交瘤细胞株、其分泌的单克隆抗体及应用
US12384847B2 (en) 2018-02-08 2025-08-12 Dragonfly Therapeutics, Inc. Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US12215157B2 (en) 2018-02-20 2025-02-04 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use
EP3775251A1 (en) 2018-03-26 2021-02-17 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
MA53284A (fr) 2018-08-08 2022-01-26 Dragonfly Therapeutics Inc Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
BR112021022405A2 (pt) * 2019-05-09 2022-04-19 Merus Nv Domínios variantes para multimerização de proteínas e separação das mesmas
CA3152547A1 (en) 2019-09-26 2021-04-01 Amgen Inc. Methods of producing antibody compositions
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
TW202208428A (zh) 2020-05-06 2022-03-01 美商蜻蜓醫療公司 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
JP2023548767A (ja) 2020-10-15 2023-11-21 アムジエン・インコーポレーテツド 抗体製造方法における相対不対グリカン
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
WO2022261021A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
EP4413377A1 (en) 2021-10-05 2024-08-14 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023122211A2 (en) * 2021-12-21 2023-06-29 Duke University Coronavirus antibodies and uses thereof
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2023213400A1 (en) * 2022-05-05 2023-11-09 Institute For Research In Biomedicine Antibodies against chemokines, method for identifying said antibodies and uses thereof
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
JPH0967399A (ja) * 1995-08-30 1997-03-11 Mitsui Toatsu Chem Inc 抗ｍｃｐ−１ヒトモノクローナル抗体
JP3996191B2 (ja) * 1995-09-27 2007-10-24 塩野義製薬株式会社 Ｃｃ型ケモカイン様タンパク質
JPH1160502A (ja) * 1997-08-12 1999-03-02 Teijin Ltd 脳梗塞症治療薬もしくは予防薬
EP1286698A1 (en) 2000-05-19 2003-03-05 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods for reducing tumor growth and metastasis by inhibiting mcp-1 activity
GB0016138D0 (en) * 2000-06-30 2000-08-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
NZ542784A (en) 2008-07-31
US7482434B2 (en) 2009-01-27
JP4468172B2 (ja) 2010-05-26
EP1542724A2 (en) 2005-06-22
UA87979C2 (ru) 2009-09-10
CO6220978A2 (es) 2010-11-19
US20050058639A1 (en) 2005-03-17
CA2496419A1 (en) 2004-02-26
US20070128112A1 (en) 2007-06-07
RU2339647C2 (ru) 2008-11-27
AU2003265575B2 (en) 2009-12-10
US7202343B2 (en) 2007-04-10
RS20050834A (sr) 2007-12-31
EP1542724A4 (en) 2005-10-19
US7687606B2 (en) 2010-03-30
WO2004016769A3 (en) 2004-10-14
IL171674A0 (en) 2009-02-11
ZA200508994B (en) 2006-09-27
WO2004016769A2 (en) 2004-02-26
IS8115A (is) 2005-11-01
HRP20050986A2 (en) 2006-11-30
MEP18108A (en) 2010-06-10
LT5416B (lt) 2007-04-25
RU2005134354A (ru) 2006-06-10
US20070116708A1 (en) 2007-05-24
JP2005536534A (ja) 2005-12-02
AU2003265575A1 (en) 2004-03-03

Similar Documents

Publication Publication Date Title
LT2005099A (lt) ANTIKuNAI, NUKREIPTI PRIES MONOCITO CHEMOTAKSIO BALTYMA -1, IR JU PANAUDOJIMAS
MXPA05005925A (es) Anticuerpos dirigidos a la fosfolipasa a2 y sus usos.
TW200716182A (en) Antibodies directed to CD20 and uses thereof
TW200637873A (en) Antibodies against interleukin-1 beta
TW200634027A (en) Antibodies directed to angiopoietin-2 and uses thereof
EP1578799A4 (en) ANTIBODIES THAT AFFECT TUMOR NECROSIS FACTOR (TNF) AND THEIR USE
WO2003057857A3 (en) Antibodies directed to pdgfd and uses thereof
SG155883A1 (en) Anti-cd3 antibodies and methods of use thereof
WO2006052591A3 (en) Anti-properdin antibodies, and methods for making and using same
IL173323A0 (en) Antibodies directed to parathyroid hormone (pth) and uses thereof
WO2007120693A3 (en) Targeted binding agents directed to upar and uses thereof
WO2004084823A3 (en) Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
WO2008112004A3 (en) ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
WO1998050433A3 (en) Human monoclonal antibodies to epidermal growth factor receptor
WO2006104978A3 (en) Antibodies against the tenascin major antigens
WO2007109307A3 (en) Antibodies directed to angiopoietin-like protein 4 and uses thereof
CU23292B7 (es) Anticuerpos monoclonales humanos de ctla-4
ATE492563T1 (de) Vollständige humane monoklonale antikörper gegen il-13
WO2006039258A3 (en) Human antibodies against parathyroid hormone
WO2007065037A3 (en) Antibodies against mmp-13 (collagenase-3) and uses thereof

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20100819